Vantage Biosciences is a UK-based clinical stage biotechnology company targeting the root cause of vision loss resulting from diabetes – the neuroinflammatory insult that precedes microangiopathy and leads to degeneration of the neurovascular unit of the eye. Our mission is to enable patient access to disease modifying therapy for diabetic eye disease by developing drugs that intervene at the earliest point of disease biology.
Company Details
- Employees
- 6
- Founded
- 2023
- Address
- London, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- London
Vantage Biosciences Questions
Vantage Biosciences's website is https://www.vantage-biosciences.com/
Vantage Biosciences's LinkedIn profile is https://uk.linkedin.com/company/vantage-biosciences
Vantage Biosciences has
6 employees.
View email and phone details for 6
employees at Vantage Biosciences.
Vantage Biosciences's industry is
Biotechnology Research
Vantage Biosciences's top competitors are
Relation,
Oxford Biotherapeutics,
Epsilogen Ltd,
Axovia Therapeutics,
Pykus Therapeutics,
Alsa Ventures,
Vertex Pharmaceuticals,
Lifearc Ventures,
Promatix Biosciences Ltd,
Bvi Medical.
Vantage Biosciences's categories are Biotechnology Research
Vantage Biosciences's founding year is 2023
